The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga. “Our view is that in the long term, this is not a two-horse race between Eli Lilly Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO),” Maurits stated, challenging the prevailing notion of a duopoly in the weight-loss market. Pot predicts that rising demand for weight loss treatments and expanded applications for GLP-1 drugs will drive this trillion-dollar market opportunity. In November 2023, Tema ETFs launched the Tema GLP-1, Obesity and Cardiometabolic ETF (NYSE:HRTS), the first ETF focused on weight loss. Since inception, the fund has risen 25%, slightly outpacing the performance of the S&P 500, as tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY). The ETF's major holdings include Eli Lilly and Company, Amgen Inc. (NASDAQ:AMGN), Novo Nordisk A/S, and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), each with about 5-6% weight. The HRTS portfolio also comprises over 40 other weight-loss related companies. Chart: Tema GLP-1, Obesity And Cardiometabolic ETF Outperforms S&P 500 Since Inception